Rechercher des projets européens

10 projets européens trouvés

Recherche sur 125080 projets européens

 EN COURS 

Human Puripotent Stem Cell Registry (hPSCreg)

Date du début: 1 janv. 2017, Date de fin: 31 déc. 2021,

European registry for human embryonic stem cell lines
Voir le projet

 2

 TERMINÉ 
PACE aims to transform the treatment of patients suffering from critical limb ischemia (CLI), a disease with high medical need, because of limited treatment options and poor outcome by applying a novel, off-the-shelf allogeneic placenta-derived stromal cell product (PLX-PAD). Despite improvements in medical care and revascularization, patients with CLI continue to have a high risk of major amputat ...
Voir le projet

 9

 TERMINÉ 
HarmonicSS vision is to create an International Network and Alliance of partners and cohorts, entrusted with the mission of addressing the unmet needs in primary Sjogren Syndrome; working together to create and maintain a platform with open standards and tools, designed to enable secure storage, governance, analytics, access control and controlled sharing of information at multiple levels along wi ...
Voir le projet

 39

 TERMINÉ 
We concur to the IMI on “Reclassification of SLE, connective tissue diseases and RA” call by presenting a proposal aimed at using the power of OMICs, and bioinformatics to identify new classifications for diseases known to share common pathophysiological mechanisms. Such knowledge has not been applied to individual patients, depriving them from potential benefits in terms of the use of new therape ...
Voir le projet

 30

 TERMINÉ 

BeTheCuRE (BTCURE)

Date du début: 1 avr. 2011, Date de fin: 31 mars 2017,

BTCure is based on the recognition that RA is a heterogeneous disease where a major subset involves adaptive immunity, and that animal models have to develop the line with the different subsets of the human diseases in order to be optimally used for drug discovery and drug evaluation. Our aim is to develop an understanding of the early process in human arthritis subsets and the animal models that ...
Voir le projet

 41

 TERMINÉ 
"Immunological memory provides immunity against recurrent pathogens, but also can induce and regulate immunopathology. In chronic immune-mediated diseases, a ""pathogenic"" immunological memory probably is the essential driver of inflammation, refractory to physiological regulation and state-of-the-art therapeutic immunosuppression, and thus a challenge for the development of novel, curative thera ...
Voir le projet

 1

 TERMINÉ 
Inflammatory rheumatic diseases affect millions of European citizens causing chronic pain, disability and premature death. Curative treatments are lacking. Conventional research often focuses on one single organ system such as the bone or the immune system and. ignores interactions between organ systems. OSTEOIMMUNE is a supra-disciplinary training network that targets this gap by providing compre ...
Voir le projet

 12

 TERMINÉ 

The role of NKG2D in CD4+ T cell function and autoimmunity (NKG2D-IMMUNO)

Date du début: 1 mai 2013, Date de fin: 29 mai 2016,

More than 5 million people in Europe live with inflammatory bowel disease (IBD) or rheumatoid arthritis (RA). Both diseases are characterized by chronic inflammation partially mediated by inappropriate T cell response. Effector T-cell responses can be modulated by competing positive or negative costimulatory signals, and dysregulated balance between these signals may lead to chronic autoimmune inf ...
Voir le projet

 1

 TERMINÉ 
Immune-mediated inflammatory diseases (IMID) are important health challenges in Europe and beyond, afflicting an estimated 5-8% of the total population. IMID with an onset during childhood such as Juvenile Idiopathic Arthritis (JIA) cause particular concern as pediatric patients form an especially vulnerable group. Currently there is no safe and cost-effective cure for JIA and related juvenile IMI ...
Voir le projet

 11

 TERMINÉ 
Until the age of biotechnology, treatment options for children and adolescents with severe arthritis, inflammatory bowel diseases and other serious diseases with chronic inflammation were limited. Advances in understanding the pathophysiology of the inflammatory responses have led to the development of a new class of medications that are capable of inhibiting selectively the principal mediators of ...
Voir le projet

 9